Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 2 months ago

Save on this medicine

Other brands with the same active ingredient

These brands contain the same active ingredient (Cyclobenzaprine Hydrochloride). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.

Indications & Uses

Laxirin is indicated for:

Dosage Reference

Reference Information Only

Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.

Adults:

The usual dose is 5-10 mg three times daily given by mouth. The daily dose should not exceed 60 mg. Treatment for more than 2 or 3 weeks is not recommended.Dose in elderly: Therapy with Flexor in the elderly should be initiated with a 5 mg dose and titrated slowly upward.Dose in hepatic impairment: Flexor should be used with caution in subjects with mild hepatic impairment starting with the 5 mg dose and titrating slowly upward. The use of Flexor in subjects with moderate to severe impairment is not recommended.Pediatric use: Safety and effectiveness of Cyclobenzaprine Hydrochloride in pediatric patients below 15 years of age have not been established.

Side Effects

Flexor's most commonly reported side effects are drowsiness, dry mouth, and dizziness. Interestingly, these effects turned up less often in real-world surveillance than they did during the original controlled clinical trials.

Cautions & Contraindications

Warnings & Precautions

Because Flexor has atropine-like effects, it should be used cautiously in patients with a history of urinary retention, angle-closure glaucoma, or raised eye (intraocular) pressure, as well as in those already taking anticholinergic medicines.

Contraindications

Hypersensitivity to any component of this product. Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures, and deaths have occurred in patients receiving Cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs. Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. Hyperthyroidism.

Last updated: 15 Aug 2026